An octadecapeptide, H-Arg-Lys-Asp-Val-Tyr-Val-Gln-Leu-Tyr-Leu-Gln-Thr-Leu-Thr-Ala-Val-Lys-Arg-OH, corresponding to the C-terminal portion of thymopoietin II was synthesized using protecting groups removable by hydrogen fluoride treatment. The in vitro addition of the synthetic octadecapeptide was able to restore the low E-rosette forming capacity of cells in a rheumatoid arthritis patient to normal levels. The in vitro effects of pentapeptide (positions 32-36), nonapeptide (positions 33-41) and decapeptide (positions 32-41) fragments of thymopoietin on the low E-rosette forming capacity of cells of a rheumatoid arthritis patient were also compared with that of the synthetic octadecapeptide. The relative potency of the pentapeptide was 10.56 and that of the decapeptide was 25.43 based on the octadecapeptide (100.00) as a standard, but the nonapeptide was ineffective.
一种十八肽,H-Arg-Lys-Asp-Val-Tyr-Val-Gln-Leu-Tyr-Leu-Gln-Thr-Leu-Thr-Ala-Val-Lys-Arg-OH,对应于
胸腺生成素II的C端部分,通过使用
氢氟酸处理可去除的保护基团进行合成。体外添加这种合成的十八肽能够将类风湿关节炎患者细胞的低E玫瑰花结形成能力恢复到正常
水平。还比较了
胸腺生成素的三肽(位置32-36)、九肽(位置33-41)和十肽(位置32-41)片段对类风湿关节炎患者低E玫瑰花结形成细胞的体外效应与合成十八肽的效应。基于十八肽(100.00)作为标准,三肽的相对效力为10.56,十肽为25.43,但九肽无效。